Frontlight ResearchEarly access
CompletedNo phase
Endogenous Lithium Clearance in Acute Kidney Injury
Key facts
- Who runs it
- University Hospital of North Norway
- Where
- Norway1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 1 Aug 2023
- Ended
- 20 May 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Lithium clearance
- Record updated
- 22 June 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- ICU patients diagnosed with AKI, without AKI and healthy controls
Who cannot take part
- -
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Critically ill patients are at high risk of developing acute kidney injury (AKI). Lithium is freely filtrated at the glomerulus and almost completely reabsorbed in the proximal tubule, which provides a quantitative estimation of proximal tubule reabsorption. The investigators hypothesized that endogenous lithium reabsorption is impaired in the early stages of critical illness.
Read full original descriptionShow less
Investigators would like to study 10 ICU patients with AKI diagnosed, 10 patients without AKI, and 10 healthy controls.
The 2 groups in the trial
- Group 1
ICU patients with AKI
Treatment: Lithium clearance
- Group 2
ICU patients with normal renal function
Treatment: Lithium clearance
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 22 June 2025